Varicella Routine Vaccination and the Effects on Varicella Epidemiology - Results from the Bavarian Varicella Surveillance Project (BaVariPro), 2006-2011
Overview
Affiliations
Background: In 2004, routine varicella vaccination was recommended in Germany for children 11-14 months of age with one dose, and since 2009, with a second dose at 15-23 months of age. The effects on varicella epidemiology were investigated.
Methods: Data on varicella vaccinations, cases and complications were collected from annual parent surveys (2006-2011), monthly paediatric practice surveillance (Oct 2006 - Sep 2011; five varicella seasons) and paediatric hospital databases (2005-2009) in the area of Munich (about 238,000 paediatric inhabitants); annual incidences of cases and hospitalisations were estimated.
Results: Varicella vaccination coverage (1st dose) in children 18-36 months of age increased in two steps (38%, 51%, 53%, 53%, 66% and 68%); second-dose coverage reached 59% in the 2011 survey. A monthly mean of 82 (62%) practices participated; they applied a total of 50,059 first-dose and 40,541 second-dose varicella vaccinations, with preferential use of combined MMR-varicella vaccine after recommendation of two doses, and reported a total of 16,054 varicella cases <17 years of age. The mean number of cases decreased by 67% in two steps, from 6.6 (95%CI 6.1-7.0) per 1,000 patient contacts in season 2006/07 to 4.2 (95%CI 3.9-4.6) in 2007/08 and 4.0 (95%CI 3.6-4.3) in 2008/09, and further to 2.3 (95%CI 2.0-2.6) in 2009/10 and 2.2 (95%CI 1.9-2.5) in 2010/11. The decrease occurred in all paediatric age groups, indicating herd protection effects. Incidence of varicella was estimated as 78/1,000 children <17 years of age in 2006/07, and 19/1,000 in 2010/11. Vaccinated cases increased from 0.3 (95%0.2-0.3) per 1,000 patient contacts in 2006/07 to 0.4 (95%CI 0.3-0.5) until 2008/09 and decreased to 0.2 (95%CI 0.2-0.3) until 2010/11. The practices treated a total of 134 complicated cases, mainly with skin complications. The paediatric hospitals recorded a total of 178 varicella patients, including 40 (22.5%) with neurological complications and one (0.6%) fatality due to varicella pneumonia. Incidence of hospitalisations decreased from 7.6 per 100,000 children <17 years of age in 2005 to 4.3 in 2009, and from 21.0 to 4.7 in children <5 years of age.
Conclusions: Overall, the results show increasing acceptance and a strong impact of the varicella vaccination program, even with still suboptimal vaccination coverage.
Xuan K, Zhang N, Li T, Pang X, Li Q, Zhao T JMIR Public Health Surveill. 2024; 10:e50673.
PMID: 38579276 PMC: 11031691. DOI: 10.2196/50673.
Global Prevalence of Varicella-Associated Complications: A Systematic Review and Meta-Analysis.
Shah H, Meiwald A, Perera C, Casabona G, Richmond P, Jamet N Infect Dis Ther. 2023; 13(1):79-103.
PMID: 38117427 PMC: 10828225. DOI: 10.1007/s40121-023-00899-7.
Qiu L, Liu S, Zhang M, Zhong G, Peng S, Quan J BMC Public Health. 2023; 23(1):1875.
PMID: 37770829 PMC: 10537126. DOI: 10.1186/s12889-023-16304-4.
Barrero Guevara L, Goult E, Rodriguez D, Hernandez L, Kaufer B, Kurth T J Infect Dis. 2023; 228(6):674-683.
PMID: 37384795 PMC: 10503957. DOI: 10.1093/infdis/jiad244.
Global varicella vaccination programs.
Lee Y, Choe Y, Lee J, Kim E, Lee J, Hong K Clin Exp Pediatr. 2022; 65(12):555-562.
PMID: 36457198 PMC: 9742762. DOI: 10.3345/cep.2021.01564.